Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 14:12:922120.
doi: 10.3389/fonc.2022.922120. eCollection 2022.

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients

Tingting Cheng  1   2   3   4 , Yan Chen  1   2   3   4 , Yi Liu  1   2   3   4 , Xia Ma  1   2   3   4 , Cong Zeng  1   2   3   4 , Xu Chen  1   2   3   4 , Shiyu Wang  1   2   3   4 , Yajing Xu  1   2   3   4
Affiliations

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients

Tingting Cheng et al. Front Oncol. .

Abstract

Recent studies have shown that haploidentical hematopoietic stem cell transplantation supported by third-party cord blood (haplo-cord-HSCT) results in rapid hematopoietic recovery, low incidences of graft-versus-host disease (GVHD), and relapse of hematologic malignancies. However, few reports on haploidentical peripheral blood stem cell transplantation supported by third-party cord blood (haplo-cord-PBSCT) have been published. To evaluate the outcomes of patients who underwent haplo-cord-PBSCT or human leukocyte antigen (HLA)-matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT), we retrospectively reviewed the clinical data of patients with hematologic malignancies who underwent haplo-cord-PBSCT (n = 93) or MSD-PBSCT (n = 72) in our hospital from March 2017 to December 2020. In the haplo-cord-PBSCT and MSD-PBSCT groups, the median time for neutrophil and platelet engraftment was 13 vs. 12 days (p = 0.07) and 16 vs. 13 days (p = 0.06), respectively. The 30-day cumulative incidences of neutrophil engraftment were 100.0% and 98.6% (p = 0.12). The 100-day cumulative incidences of platelet engraftment were 96.8% and 98.6% (p = 0.01). The 100-day cumulative incidences of grade II-IV and grade III-IV acute GVHD were 29.1% vs. 23.6% (p = 0.42) and 9.7% vs. 4.2% (p = 0.18). The cumulative incidences of total and moderate/severe chronic GVHD at 1 year were 26.5% vs. 17.4% and 8.1% vs. 4.5%, respectively, and at 3 years were 34.7% vs. 34.3% (p = 0.60) and 13.6% vs. 10.6% (p = 0.49), respectively. The cumulative incidences of relapse at 1 year were 9.3% and 7.2% and at 3 years were 17.0% and 17.0% (p = 0.98). Non-relapse mortality (NRM) at 1 year was 14.6% and 8.6% and at 3 years was 17.4% and 8.6% (p = 0.13) in two groups. The probabilities of overall survival (OS), disease-free survival (DFS), and GVHD-free/relapse-free survival (GRFS) at 1 year were 81.7% vs. 88.6%, 76.1% vs. 84.2%, and 71.7% vs. 79.7%, respectively, and at 3 years were 78.7% vs. 79.0%, 65.6% vs. 74.4%, and 55.5% vs. 63.6%, respectively, in the corresponding group, p > 0.05. In conclusion, for patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) and acute lymphoid leukemia (ALL), haplo-cord-PBSCT results in similar outcomes compared with MSD-PBSCT, and it may be a valid alternative transplantation method.

Keywords: HLA-matched sibling donor; cord blood; haploidentical donor; hematologic malignancy; peripheral blood; stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Assessment of hematopoietic recovery after transplantation in haplo-cord group and MSD group: (A) cumulative incidence of neutrophil engraftment and (B) cumulative incidence of platelet engraftment. MSD, matched sibling donor.
Figure 2
Figure 2
Assessment of cumulative incidence of aGVHD in haplo-cord group and MSD group: (A) grade II–IV aGVHD and (B) grade III–IV aGVHD. aGVHD, acute graft-versus-host disease; MSD, matched sibling donor.
Figure 3
Figure 3
Assessment of cumulative incidence of cGVHD in haplo-cord group and MSD group: (A) all grades of cGVHD and (B) cGVHD (moderate/severe). cGVHD, chronic graft-versus-host disease; MSD, matched sibling donor.
Figure 4
Figure 4
Comparisons of outcomes between the haplo-cord group and the MSD group: (A) cumulative incidence of NRM and (B) cumulative incidence of relapse. MSD, matched sibling donor; NRM, non-relapse mortality.
Figure 5
Figure 5
Comparisons of survival rates in haplo-cord group and MSD group. (A) Overall survival (OS). (B) Disease-free survival (DFS). (C) GVHD/relapse-free survival (GRFS). MSD, matched sibling donor; GVHD, graft-versus-host disease.
See this image and copyright information in PMC

References

    1. Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of Haploidentical Stem Cell Transplantation Continues to Increase: The 2015 European Society for Blood and Marrow Transplant Activity Survey Report. Bone Marrow Transplant (2017) 52(6):811–17. doi: 10.1038/bmt.2017.34 - DOI - PMC - PubMed
    1. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic Stem Cell Transplantation Activity Worldwide in 2012 and a Swot Analysis of the Worldwide Network for Blood and Marrow Transplantation Group Including the Global Survey. Bone Marrow Transplant (2016) 51(6):778–85. doi: 10.1038/bmt.2016.18 - DOI - PMC - PubMed
    1. Xu LP, Lu PH, Wu DP, Sun ZM, Liu QF, Han MZ, et al. Hematopoietic Stem Cell Transplantation Activity in China 2019: A Report From the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant (2021) 56(12):2940–47. doi: 10.1038/s41409-021-01431-6 - DOI - PMC - PubMed
    1. Wang Y, Wu DP, Liu QF, Xu LP, Liu KY, Zhang XH, et al. Low-Dose Post-Transplant Cyclophosphamide and Anti-Thymocyte Globulin as an Effective Strategy for Gvhd Prevention in Haploidentical Patients. J Hematol Oncol (2019) 12(1):88. doi: 10.1186/s13045-019-0781-y - DOI - PMC - PubMed
    1. Nagler A, Kanate AS, Labopin M, Ciceri F, Angelucci E, Koc Y, et al. Post-Transplant Cyclophosphamide Versus Anti-Thymocyte Globulin for Graft-Versus-Host Disease Prevention in Haploidentical Transplantation for Adult Acute Lymphoblastic Leukemia. Haematologica (2021) 106(6):1591–98. doi: 10.3324/haematol.2020.247296 - DOI - PMC - PubMed